Metabolic syndrome in liver transplant recipients: Prevalence, risk factors, and association with cardiovascular events

Liver Transplantation

Volumn 17, Issue 1, 2011, Pages 15-22

  Laish, Ido ^a   Braun, Marius ^a   Mor, Eytan ^a   Sulkes, Jaqueline ^a   Harif, Yael ^a   Ari, Ziv Ben ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ALCOHOL LIVER CIRRHOSIS; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GRAFT FAILURE; HEPATITIS C; HUMAN; HYPERTENSION; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; OBESITY; PARAMETER; PREVALENCE; PRIORITY JOURNAL; RECURRENT DISEASE; RISK FACTOR; SEPSIS;

ADULT; AGED; CARDIOVASCULAR DISEASES; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; ISRAEL; LIVER TRANSPLANTATION; LOGISTIC MODELS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; ODDS RATIO; PREVALENCE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 79251488789     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.22198     Document Type: Article

References (37)

1. Canzanello VJ, Schwartz L, Taler SJ, Textor SC, Wiesner RH, Porayko MK, Krom RA,. Evolution of cardiovascular risk after liver transplantation: a comparison of cyclosporine A and tacrolimus (FK506). Liver Transpl Surg 1997; 3: 1-9.
2. Stegall MD, Everson G, Schroter G, Bilir B, Karrer F, Kam I., Metabolic complications after liver transplantation. Diabetes, hypercholesterolemia, hypertension, and obesity. Transplantation 1995; 60: 1057-1060.
3. Saab S, Shpaner A, Zhao Y, Brito I, Durazo F, Han S, et al. Prevalence and risk factors for diabetes mellitus in moderate term survivors of liver transplantation. Am J Transplant 2006; 6: 1890-1895.
4. Laryea M, Watt KD, Molinari M, Waish MJ, McAllister VC, Marotta PJ, et al. Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. Liver Transpl 2007; 13: 1109-1114.
5. Gisbert C, Prieto M, Berenguer M, Bretõ M, Carrasco D, de Juan M, et al. Hyperlipidemia in liver transplant recipients: prevalence and risk factors. Liver Transpl Surg 1997; 3: 416-422.
6. Richards J, Gunson B, Johnson J, Neuberger J., Weight gain and obesity after liver transplantation. Transpl Int 2005; 18: 461-466.
7. TD Correia MI, Rego LO, Lima AS., Post-liver transplant obesity and diabetes. Curr Opin Clin Nutr Metab Care 2003; 6: 457-460.
8. Marchetti P, Navalesi R., The metabolic effects of cyclosporine and tacrolimus. J Endocrinol Invest 2000; 23: 482-490.
9. Hakeam HA, Al-Jedai AH, Raza SM, Hamawi K., Sirolimus induced dyslipidemia in tacrolimus based vs. tacrolimus free immunosuppressive regimens in renal transplant recipients. Ann Transplant 2008; 13: 46-53.
10. Bigam DL, Pennington JJ, Carpentier A, Wanless IR, Hemming AW, Croxford R, et al. Hepatitis C-related cirrhosis: a predictor of diabetes after liver transplantation. Hepatology 2000; 32: 87-90.
11. Delgado-Borrego A, Liu YS, Jordan SH, Agrawal S, Zhang H, Christofi M, et al. Prospective study on liver transplant recipients with HCV infection: evidence of a causal relationship between HCV and insulin resistance. Liver Transpl 2008; 14: 193-201.
12. Contos MJ, Cales W, Sterling RK, Luketic VA, Shiffman ML, Mills AS, et al. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl 2001; 7: 363-373.
13. Cauble MS, Gilroy R, Sorrell MF, Mailliard ME, Sudan DL, Anderson JC, et al. Lipoatrophic diabetes and end-stage liver disease secondary to nonalcoholic steatohepatitis with recurrence after liver transplantation. Transplantation 2001; 71: 892-895.
14. Angelico F, Del Ben M, Francioso S, Hurtova M, Battista S, Palmieri GP, et al. Recurrence of insulin resistant metabolic syndrome following liver transplantation. Eur J Gastroenterol Hepatol 2003; 15: 99-102.
15. Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ, Pio JR, Williams GR,. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 2004; 110: 1245-1250.
16. Kasiske BL., Epidemiology of cardiovascular disease after renal transplantation. Transplantation 2001; 72 (Suppl 6): S5-S8.
17. Pruthi J, Medkiff KA, Esrason KT, Donovan JA, Yoshida EM, Erb SR, et al. Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver Transpl 2001; 7: 811-815.
18. Johnston SD, Morris JK, Cramb R, Gunson BK, Neuberger J., Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation 2002; 73: 901-906.
19. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC., Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
20. McAuley KA, Williams SM, Mann JI, Waiker RJ, Lewis-Barned NJ, Temple LA, Duncan AW,. Diagnosing insulin resistance in the general population. Diabetes Care 2001; 24: 460-464.
21. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
22. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-2752.
23. Ford ES, Giles WH, Dietz WH., Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-359.
24. Mells G, Neuberger J., Reducing the risks of cardiovascular disease in liver allograft recipients. Transplantation 2007; 83: 1141-1150.
25. Bostom AD, Brown RS Jr, Chavers BM, Coffman TM, Cosio FG, Culver K, et al. Prevention of post-transplant cardiovascular disease - report and recommendations of an ad hoc group. Am J Transplant 2002; 2: 491-500.
26. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ., Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999; 29: 664-669.
27. Ong J, Younossi ZM, Reddy V, Price LL, Gramlich T, Mayes J, Boparai N,. Cryptogenic cirrhosis and posttransplantation nonalcoholic fatty liver disease. Liver Transpl 2001; 7: 797-801.
28. Malik SM, de-Vera ME, Fontes P, Shaikh O, Ahmad J., Outcome after liver transplantation for NASH cirrhosis. Am J Transplant 2009; 9: 782-793.
29. Hanouneh IA, Feldstein AE, McCullough AJ, Miller C, Aucejo F, Yerian L, et al. The significance of metabolic syndrome in the setting of recurrent hepatitis C after liver transplantation. Liver Transpl 2008; 14: 1287-1293.
30. Khalili M, Lim JM, Bass N, Ascher NL, Roberts JP, Terrault NA., New onset diabetes mellitus after liver transplantation: the critical role of hepatitis C infection. Liver Transpl 2004; 10: 349-355.
31. Hadziyannis SJ., The spectrum of extrahepatic manifestations in hepatitis C virus infection. J Viral Hepatol 1997; 4: 9-28.
32. Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Tsukamoto K, Kimura S, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004; 126: 840-848.
33. Bianchi G, Marchesini G, Marzocchi R, Pinna AD, Zoli M., Metabolic syndrome in liver transplantation: relation to etiology and immunosuppression. Liver Transpl 2008; 14: 1648-1654.
34. Ciccarelli O, Kaczmarek B, Roggen F, DeReyck C, Goffette P, Danse E, et al. Long-term medical complications and quality of life in adult recipients surviving 10 years or more after liver transplantation. Acta Gastroenterol Belg 2005; 68: 323-330.
35. Sheiner PA, Magliocca JF, Bodian CA, Kim-Schluger L, Altaca G, Guarera JV, et al. Long-term medical complications in patients surviving > or = 5 years after liver transplant. Transplantation 2000; 69: 781-789.
36. Neal DA, Tom BD, Luan J, Wareham NJ, Gimson AE, Delriviere LD, et al. Is there disparity between risk and incidence of cardiovascular disease after liver transplant ? Transplantation 2004; 77: 93-99.
37. Rabkin JM, Corless CL, Rosen HR, Olyaei AJ., Immunosuppression impact on long-term cardiovascular complications after liver transplantation. Am J Surg 2002; 183: 595-599.